[go: up one dir, main page]

HRP20190841T1 - Injektabilna formulacija - Google Patents

Injektabilna formulacija

Info

Publication number
HRP20190841T1
HRP20190841T1 HRP20190841TT HRP20190841T HRP20190841T1 HR P20190841 T1 HRP20190841 T1 HR P20190841T1 HR P20190841T T HRP20190841T T HR P20190841TT HR P20190841 T HRP20190841 T HR P20190841T HR P20190841 T1 HRP20190841 T1 HR P20190841T1
Authority
HR
Croatia
Prior art keywords
injectable formulation
injectable
formulation
Prior art date
Application number
HRP20190841TT
Other languages
English (en)
Inventor
Tetsuya Sato
Takuya MINOWA
Yusuke HOSHIKA
Hidekazu TOYOFUKU
Original Assignee
Otsuka Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49483139&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20190841(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharmaceutical Co., Ltd. filed Critical Otsuka Pharmaceutical Co., Ltd.
Publication of HRP20190841T1 publication Critical patent/HRP20190841T1/hr
Publication of HRP20190841T4 publication Critical patent/HRP20190841T4/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20190841TT 2012-04-23 2013-04-23 Injektabilna formulacija HRP20190841T4 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261636932P 2012-04-23 2012-04-23
US201361791896P 2013-03-15 2013-03-15
EP13781458.8A EP2868318B2 (en) 2012-04-23 2013-04-23 Injectable formulation
PCT/JP2013/061950 WO2013161830A1 (ja) 2012-04-23 2013-04-23 注射製剤

Publications (2)

Publication Number Publication Date
HRP20190841T1 true HRP20190841T1 (hr) 2019-07-26
HRP20190841T4 HRP20190841T4 (hr) 2022-03-04

Family

ID=49483139

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20190841TT HRP20190841T4 (hr) 2012-04-23 2013-04-23 Injektabilna formulacija

Country Status (31)

Country Link
US (5) US20150086632A1 (hr)
EP (1) EP2868318B2 (hr)
JP (1) JP6249944B2 (hr)
KR (1) KR102168263B1 (hr)
CN (4) CN110638752A (hr)
AR (1) AR090775A1 (hr)
AU (1) AU2013253518B2 (hr)
BR (1) BR112014026398B1 (hr)
CA (1) CA2871398C (hr)
CO (1) CO7151499A2 (hr)
CY (1) CY1123195T1 (hr)
DK (1) DK2868318T4 (hr)
EA (1) EA026124B1 (hr)
ES (1) ES2727454T5 (hr)
HR (1) HRP20190841T4 (hr)
HU (1) HUE043686T2 (hr)
IL (1) IL235211A0 (hr)
IN (1) IN2014DN08870A (hr)
JO (1) JO3524B1 (hr)
LT (1) LT2868318T (hr)
MX (1) MX361722B (hr)
MY (1) MY169099A (hr)
NZ (1) NZ630255A (hr)
PH (1) PH12014502366A1 (hr)
PL (1) PL2868318T5 (hr)
PT (1) PT2868318T (hr)
SG (2) SG10201608684QA (hr)
SI (1) SI2868318T2 (hr)
TW (1) TWI641395B (hr)
UA (1) UA118084C2 (hr)
WO (1) WO2013161830A1 (hr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
TWI562991B (en) * 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
JOP20210047A1 (ar) * 2012-10-25 2017-06-16 Otsuka Pharma Co Ltd عامل وقائي و/أو علاجي للأعراض السلوكية والنفسية المصحوبة بمرض تنكسي عصبي أو الأعراض الإندفاعية المصحوبة بمرض ذهني، يحتوي على بريكسبيرازول أو ملحه
WO2017106641A1 (en) * 2015-12-17 2017-06-22 Assia Chemical Industries Ltd. Solid state forms of brexpiprazole
WO2017134038A1 (en) * 2016-02-01 2017-08-10 Hexal Ag Anhydrate-free polymorphically pure micronized crystalline brexpiprazole dihydrate for use in intramuscular injectable sustained release formulations
WO2017208251A1 (en) * 2016-05-31 2017-12-07 Cipla Limited A new stable polymorph of brexpiprazole and process for preparation thereof
WO2018033483A1 (en) * 2016-08-16 2018-02-22 H E X A L Aktiengesellschaft Pharmaceutical compositions of a benzothiophene compound
WO2018141886A1 (en) * 2017-02-02 2018-08-09 Hexal Aktiengesellschaft Crystalline brexpiprazole
CN113645954B (zh) * 2019-03-28 2024-03-29 大塚制药株式会社 含有苯并氮杂卓化合物的冻干组合物
JPWO2021029020A1 (hr) * 2019-08-13 2021-02-18
CA3225183A1 (en) * 2021-09-07 2023-03-16 Ming Li Long-acting brexpiprazole preparation for injection and preparation method therefor
CN117214053A (zh) * 2023-10-17 2023-12-12 海南卫康制药(潜山)有限公司 一种注射用头孢呋辛钠肌注混悬液的粒度测定方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010012188A (ko) 1997-05-14 2001-02-15 요시다 쇼지 재분산성이 양호한 수성 현탁액제
JP3402195B2 (ja) * 1997-05-14 2003-04-28 千寿製薬株式会社 再分散性の良い水性懸濁液剤
US6656505B2 (en) * 2000-07-21 2003-12-02 Alpharma Uspd Inc. Method for forming an aqueous flocculated suspension
US20030195179A1 (en) 2000-08-25 2003-10-16 Shirou Sawa Aqueous suspension preparations
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US20050032811A1 (en) * 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
ES2315721T5 (es) * 2003-10-23 2012-08-24 Otsuka Pharmaceutical Co., Ltd. Formulación de aripiprazol inyectable estéril de liberación controlada y procedimiento
JP4315393B2 (ja) * 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
TWI320783B (en) * 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
EP2279727A3 (en) * 2005-09-15 2011-10-05 Elan Pharma International Limited Nanoparticulate aripiprazole formulations
TW200808375A (en) 2006-05-12 2008-02-16 Otsuka Pharma Co Ltd Hydrogel suspension and manufacturing process thereof
TWI415629B (zh) * 2006-10-26 2013-11-21 Otsuka Pharma Co Ltd 含有瑞巴匹特之水性醫藥懸浮物及其製造方法
MX2010001311A (es) * 2007-07-31 2010-04-21 Otsuka Pharma Co Ltd Metodo para producir una suspensi?n de aripiprazol y formulacion liofilizada.
JP5581227B2 (ja) * 2008-03-11 2014-08-27 アルコン リサーチ, リミテッド 硝子体内注射のための低粘度、高凝集トリアムシノロンアセトニド懸濁剤
MX2011005217A (es) * 2008-11-19 2011-06-01 Merial Ltd Formulaciones que comprenden ceftiofur y cetoprofeno o ceftiofur y alcohol bencilico.
EP2552420B1 (en) * 2010-08-24 2018-07-18 Otsuka Pharmaceutical Co., Ltd. Suspension and cake composition containing carbostyryl derivative and silicone oil and/or silicone oil derivative
WO2012053654A1 (en) * 2010-10-18 2012-04-26 Dainippon Sumitomo Pharma Co., Ltd. Sustained-release formulation for injection
LT2685979T (lt) * 2011-03-18 2016-12-12 Alkermes Pharma Ireland Limited Injekcinės farmacinės kompozicijos, apimančios vandenyje netirpų antipsichotiką, sorbitano lauratą ir polisorbatą 20
JP2012232958A (ja) 2011-05-09 2012-11-29 Otsuka Pharmaceut Co Ltd 注射製剤
EP2827866B1 (en) * 2012-03-19 2023-05-03 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
TWI562991B (en) 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن

Also Published As

Publication number Publication date
CA2871398C (en) 2021-04-27
EP2868318B1 (en) 2019-03-06
PT2868318T (pt) 2019-06-07
IL235211A0 (en) 2014-12-31
MX2014012734A (es) 2015-04-10
SG10201608684QA (en) 2016-12-29
EA026124B1 (ru) 2017-03-31
US20150086632A1 (en) 2015-03-26
CO7151499A2 (es) 2014-12-29
IN2014DN08870A (hr) 2015-05-22
US20200163960A1 (en) 2020-05-28
JO3524B1 (ar) 2020-07-05
SI2868318T1 (sl) 2019-06-28
US10624889B2 (en) 2020-04-21
EP2868318A4 (en) 2015-12-09
US20240277702A1 (en) 2024-08-22
CA2871398A1 (en) 2013-10-31
ES2727454T3 (es) 2019-10-16
SG11201406775UA (en) 2014-12-30
TWI641395B (zh) 2018-11-21
AU2013253518A1 (en) 2014-11-06
KR102168263B1 (ko) 2020-10-21
DK2868318T4 (da) 2022-03-28
HK1205678A1 (en) 2015-12-24
CN104363912A (zh) 2015-02-18
SI2868318T2 (sl) 2022-04-29
EP2868318A1 (en) 2015-05-06
DK2868318T3 (da) 2019-06-03
AR090775A1 (es) 2014-12-03
JPWO2013161830A1 (ja) 2015-12-24
PH12014502366B1 (en) 2015-01-12
EA201491937A1 (ru) 2015-03-31
BR112014026398A2 (pt) 2017-06-27
AU2013253518B2 (en) 2017-10-05
JP6249944B2 (ja) 2017-12-20
LT2868318T (lt) 2019-07-25
BR112014026398B1 (pt) 2022-11-29
HRP20190841T4 (hr) 2022-03-04
CN107536802A (zh) 2018-01-05
PL2868318T3 (pl) 2019-09-30
PL2868318T5 (pl) 2022-06-20
NZ630255A (en) 2016-05-27
EP2868318B2 (en) 2022-01-26
KR20150003336A (ko) 2015-01-08
ES2727454T5 (es) 2022-05-13
UA118084C2 (uk) 2018-11-26
CN111888329A (zh) 2020-11-06
PH12014502366A1 (en) 2015-01-12
TW201406401A (zh) 2014-02-16
MX361722B (es) 2018-12-14
US20220305007A1 (en) 2022-09-29
WO2013161830A1 (ja) 2013-10-31
CN110638752A (zh) 2020-01-03
HUE043686T2 (hu) 2019-09-30
US20180092910A1 (en) 2018-04-05
MY169099A (en) 2019-02-18
CY1123195T1 (el) 2021-10-29

Similar Documents

Publication Publication Date Title
DK3858405T3 (da) Sprøjte
DK3656373T3 (da) Sprøjte
DK2841054T3 (da) Injicerbart præparat
EP3275481C0 (en) AUTO-INJECTOR
EP2832391A4 (en) SYRINGE
BR112014032798A2 (pt) composição
DK2868318T3 (da) Injicerbar formulering
ME03413B (me) Kompozicije које sadrže peg i askorbat
EP2913076A4 (en) SYRINGE
BR112014032712A2 (pt) composição
EP2837670A4 (en) Fluorobiphenyl-containing composition
DK2811828T3 (da) Adjuvanssammensætninger
DE102012001057A8 (de) Bauteil
FR2990865B1 (fr) Autoinjecteur
FR2990863B1 (fr) Autoinjecteur
FR2990866B1 (fr) Autoinjecteur
FR2990867B1 (fr) Autoinjecteur
DK2800573T3 (da) Oftalmologisk sammensætning
FR2990862B1 (fr) Autoinjecteur
FR2990864B1 (fr) Autoinjecteur
UA24070S (uk) Ніж